Moore RD - Search Results

1

Time above 1500 copies: a viral load measure for assessing transmission risk of HIV-positive patients in care.

Marks G, Gardner LI, Rose CE, Zinski A, Moore RD, Holman S, Rodriguez AE, Sullivan M, Giordano TP. Marks G, et al. Among authors: moore rd. AIDS. 2015 May 15;29(8):947-54. doi: 10.1097/QAD.0000000000000640. AIDS. 2015. PMID: 25768835 Free PMC article.

2

Anemia in HIV-infected patients receiving highly active antiretroviral therapy.

Moore RD, Forney D. Moore RD, et al. J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):54-7. doi: 10.1097/00042560-200201010-00007. J Acquir Immune Defic Syndr. 2002. PMID: 11782590

3

Hepatitis C and progression of HIV disease.

Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Sulkowski MS, et al. Among authors: moore rd. JAMA. 2002 Jul 10;288(2):199-206. doi: 10.1001/jama.288.2.199. JAMA. 2002. PMID: 12095384

4

Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings.

Spacek LA, Griswold M, Quinn TC, Moore RD. Spacek LA, et al. Among authors: moore rd. AIDS. 2003 Jun 13;17(9):1311-7. doi: 10.1097/00002030-200306130-00005. AIDS. 2003. PMID: 12799552

5

The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons.

Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. Mehta SH, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):577-84. doi: 10.1097/00126334-200308150-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12902801

6

Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study.

Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Lucas GM, et al. Among authors: moore rd. AIDS. 2004 Feb 20;18(3):541-6. doi: 10.1097/00002030-200402200-00022. AIDS. 2004. PMID: 15090808

7

Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing.

Lucas GM, Gallant JE, Moore RD. Lucas GM, et al. Among authors: moore rd. AIDS. 2004 Jul 23;18(11):1539-48. doi: 10.1097/01.aids.0000131339.68666.1a. AIDS. 2004. PMID: 15238772

8

Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.

Gebo KA, Gallant JE, Keruly JC, Moore RD. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1028-33. doi: 10.1097/00126334-200408150-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15247555

9

Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy.

Karakousis PC, Moore RD, Chaisson RE. Karakousis PC, et al. Among authors: moore rd. Lancet Infect Dis. 2004 Sep;4(9):557-65. doi: 10.1016/S1473-3099(04)01130-2. Lancet Infect Dis. 2004. PMID: 15336223 Review.

10

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Sulkowski MS, et al. Among authors: moore rd. AIDS. 2004 Nov 19;18(17):2277-84. doi: 10.1097/00002030-200411190-00008. AIDS. 2004. PMID: 15577540

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

931 results

Search Page

Filters